跳至主要内容
临床试验/NCT07296419
NCT07296419招募中不适用

Dual System Study: Transvaginal Fetal Pulse Oximetry Measurement Systems

Raydiant Oximetry, Inc.2 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2025年12月8日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
15
试验地点
2
主要终点
Rate of device-related adverse events

研究概览

简要总结

The objective of this study is to collect and compare fetal SpO2 waveforms and reference values to inform algorithm development for signal qualification and FSpO2 calculations. Subjects are women in labor.

详细描述

The Raydiant Data Collection System (DCS) captures red and infrared waveforms that can be post-processed to calculate fetal functional oxygen saturation of arterial oxygen saturation (SpO2) and pulse rate. These waveforms are acquired from the fetus when the sensor is placed at the cheek, temple, or forehead. Acquisition of these waveforms is a necessary step toward signal qualification and data processing algorithms. The Raydiant DCS is a similar device to the original Nellcor N-400 System. Clinical research with the N-400 System demonstrated that fetal pulse oximetry values provide 54.2% positive predicative value and 92.9% sensitivity for detecting newborn metabolic acidosis (defined by pH<7.15).1 This provided a significant aid to clinicians for diagnosing endangering states of fetal hypoxia.

In this study, both the participants and the health-care providers are blinded to the oximetry data; therefore, clinical decisions regarding interventions are made based on routine clinical monitoring. The primary analysis will be performed by comparing the post-processed waveforms. Other than device placement and a period of monitoring not to exceed 6 hours, there is no change to the standard of care procedures for fetal monitoring. As stated above, the sensor displays will not be used to guide or alter patient management.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Willing and capable of providing informed consent.
  • Age > 18 years.
  • Gestational age > 36 weeks.
  • Singleton pregnancy.
  • Vertex presentation,
  • In latent or active labor,
  • Category I or II tracings,
  • Epidural anesthesia, and
  • Ruptured amniotic sac with cervical dilation of >2 cm and a station of -2 or lower.

排除标准

  • Age < 18 years.
  • Gestational age < 36 weeks
  • Multiple gestation
  • Nonvertex fetal presentation
  • Suspected vasa previa
  • Category III CTG tracing
  • Fetal anomalies and/or chromosomal disorders
  • Chorioamnionitis
  • Placenta previa
  • HIV, genital Herpes, or other infection precluding transvaginal monitoring
  • Unable to provide informed consent (e.g., cognitively impaired)
  • Low anterior placenta, or
  • Any condition (temporary or permanent) in which the investigator deems the patient unsuitable for the study procedures.

结局指标

主要结局

Rate of device-related adverse events

时间窗: Periprocedural

Rate of device-related adverse events such as erythema or rash

次要结局

  • Maternal Outcomes(Periprocedural)
  • Neonatal Outcomes(Periprocedural)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验